| [1] |
Ruoslahti E. The RGD story:a personal account. Matrix Biol[J]. 2003, 22(6):459-465.
|
| [2] |
Wickham, TJ, Mathias P, Cheresh DA, et al. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachement[J]. Cell, 1993, 73(2):309-319.
|
| [3] |
Marcinkiewicz C. Functional characteristic of snake venom disintegrins:potential therapeutic implication[J]. Curr Pharm Des, 2005, 11(7):815-827.
|
| [4] |
Ahmed N, Riley C, Rice G, et al. Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment[J]. Clin Exp Metastasis, 2005, 22(5):391-402.
|
| [5] |
Janssen ML, Oyen WJ, Dijkgraaf I, et al. Tumor targeting with radiolabeled alpha (v)beta(3) integrin binding peptides in a nude mouse model[J]. Cancer Res, 2002, 62(21):6146-6151.
|
| [6] |
Zheng DQ, Woodard AS, Fornaro M, et al. Prostatic carcinoma cell migration via alpha (v) beta (3) integrin is modulated by focal adhesion kinase pathway[J]. Cancer Res, 1999, 59(2):1655-1664.
|
| [7] |
Vonlaufen A, Wiedle G, Borisch B, et al. Integrin αvβ3 expression in colon carcinoma correlates with survival[J]. Mod Pathol, 2001, 14(11):1126-1131.
|
| [8] |
Kanamori M, Kawaguchi T, Berger MS, et al. Intracranial microenvironment reveals independent opposing functions of host alphaV beta3 expression on glioma growth and angiogenesis[J]. J Biol Chem, 2006, 281(48):37256-37264.
|
| [9] |
Zhao M, Wang C, Jiang X, et al. Synthesis of RGD containing peptides and their bioactivities[J]. Prep Biochem Biotechnol, 2002, 32(4):363-380.
|
| [10] |
Bogdanowich-Knipp SJ, Chakrabarti S, Williams TD, et al. Solution stability of linear vs. cyclic RGD peptide[J]s. J Pept Res, 1999, 53(5):530-541.
|
| [11] |
Richards J, Miller M, Abend J, et al. Engineered fibronectin type Ⅲ domain with a RGDWXE sequence binds with enhanced affinity and specificity to human alphav beta3 integrin[J]. J Mol Biol, 2003, 326(5):1475-1488.
|
| [12] |
Mitra A, Mulholland J, Nan A, et al. Targeting tumor angiogenic vasculature using polymer-RGD conjugates[J]. J Control Release, 2005, 102(1):191-201.
|
| [13] |
Chen X, Tohme M, Park R, et al. Micro-PET imaging of αvβ3-integrin expression with 18F-labeled dimeric RGD peptide[J]. Mol Imaging, 2004, 3(2):96-104.
|
| [14] |
Chen X, Park R, Tohme M, et al. Micro PET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F-and 64Cu-labeled RGD peptide[J]. Bioconjug Chem, 2004, 15(1):41-49.
|
| [15] |
Chen X, Park R, Hou Y, et al. MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide[J]. Eur J Nucl Med Mol Imaging, 2004, 31(8):1081-1089.
|
| [16] |
Chen X, Park R, ShahinianAH, et al. Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation[J]. Nuel Med Biol, 2004, 31(1):11-19.
|
| [17] |
Su ZF, Liu G, Gupta S, et al. In vitro and in vivo evaluation of a Technetiun-99m-labeled cyclic RGD peptide as a specific marker of alpha(v)beta(3)integrin for tumor imaging[J]. Bioconjug Chem, 2002, 13(3):561-570.
|
| [18] |
Haubner R, Wester HJ, Weber WA, et al. Noninvasive imaging of αvβ3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography[J]. Cancer Res, 2001, 61(5):1781-1785.
|
| [19] |
Bernard B, Capello A, van Hagen M, et al. Radiolabeled RGDDTPA-Tyr3-octreotate for receptor-targeted radionuclide therapy[J]. Cancer Biother Radiopharm, 2004, 19(2):173-180.
|